for people ages 50-80 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by Lawren VandeVrede



In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.

The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most.

To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB.

  • Clinicians use the CDR-SB to measure several categories of dementia symptoms.
  • The results for each category are added together for a total score. Lower scores are better.

Researchers will also learn more about the safety of BIIB080.

A description of how the study will be done is given below.

  • Participants will receive either a low dose or high dose of BIIB080 or a placebo as an injection into the fluid around the spinal cord. A placebo looks like the study drug but contains no real medicine.
  • The fluid around the spinal cord is called the cerebrospinal fluid.
  • Participants will be in the study for 105 weeks, or a little over 2 years. This includes the screening and follow-up periods.
  • Participants will be given BIIB080 or placebo once every 12 weeks for a total of 72 weeks.
  • Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period.
  • After the screening period, most participants will visit the clinic every 6 weeks.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia


BIIB080 is an investigational antisense therapy designed to target microtubule-associated protein tau (MAPT) mRNA and prevent production of tau protein.


Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia, Alzheimer Disease, Dementia, Cognitive Dysfunction, BIIB080


You can join if…

Open to people ages 50-80

  • Must meet all the clinical staging criteria for MCI due to AD (Stage 3) or mild AD dementia (Stage 4) according to the National Institute on Aging at National Institutes of Health and the Alzheimer's Association (NIA-AA) and must have the following at

    Screening Visit 1:

    1. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Delayed Memory Index score of ≤85, indicative of objective evidence of memory impairment
    2. CDR global score of 0.5 for MCI due to AD or 0.5 or 1 for mild AD dementia
    3. MMSE score of 22 to 30 (inclusive)
    4. CDR Memory Box score of ≥0.5
  • Evidence of amyloid pathology as measured by positive emission tomography (PET) or cerebrospinal fluid (CSF) sampling

You CAN'T join if...

  • Known allergy to BIIB080 or a history of hypersensitivity to any of the inactive ingredients in the drug product
  • Previous participation in this study or previous studies with BIIB080
  • Use of non-disease-modifying AD medications (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine) at doses that have not been stable for at least 8 weeks prior to Screening Visit 1 and during the screening period up to Study Day 1
  • Prior participation in any active or passive immunotherapy study targeting Aβ, unless documentation of receipt of placebo is available
  • Prior participation in any passive immunotherapy study targeting tau, unless the last administration occurred 6 months or 5 half-lives, whichever is sooner, prior to Screening or documentation of receipt of placebo is available
  • Participation in any study involving an investigational treatment targeting tau that is not an immunotherapy, unless documentation of receipt of placebo is available
  • Participation in a study of any other agent(s) [including gene therapy] not included in exclusion criteria 4, 5, and 6 with a purported disease-modifying effect in AD, unless documentation of receipt of placebo is available
  • Current use or previous use of medications with a purported disease-modifying effect in AD, outside of investigational studies
  • Any vaccination given within 10 days prior to Day -1. Coronavirus disease 2019 (COVID-19) vaccinations using RNA or deoxyribonucleic acid (DNA) technology are allowed during the study, as well as other types of immunization/vaccination/booster, except during the 10 days before and after clinic visits
  • Contraindications to having a brain magnetic resonance imaging (MRI) [e.g., MRI-incompatible pacemaker; MRI-incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed]. If the MRI compatibility of implanted devices is unknown, the participant must be excluded from the study
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 52 weeks prior to the Baseline Visit

    NOTE: Other protocol defined Inclusion/Exclusion criteria may apply


  • UCSF (PARENT) accepting new patients
    San Francisco California 94143 United States
  • Stanford Hospital and Clinics accepting new patients
    Palo Alto California 94304 United States

Lead Scientist at UCSF

  • Lawren VandeVrede
    Dr. Lawren VandeVrede is a neurologist who cares for patients with dementia and other memory disorders. VandeVrede's research focuses on improving scientific understanding of neurodegenerative disorders (conditions in which nerve cells progressively deteriorate or die) and developing treatments for them.


accepting new patients
Start Date
Completion Date
Phase 2 research study
Study Type
Expecting 735 study participants
Last Updated